论文部分内容阅读
形成小鼠皮下实体瘤型及腹水型肝癌Ｈ２２模型，观察低密度脂蛋白－阿克拉霉素（ＬＤＬ－ＡＣＭ）复合物和阿克拉霉素（ＡＣＭ）在荷瘤小鼠体内的抗肿瘤作用。结果表明：（１）对照组Ｈ２２实体瘤瘤重为１．７４±０．６０ｇ，ＡＣＭ组为１．３０±０．５７ｇ，ＬＤＬ－ＡＣＭ复合物组为０．８６±０．４４ｇ，与对照组差异有显著性（Ｐ＜０．０５），与ＡＣＭ组差异不明显（Ｐ＞０．０５）；（２）对照组、ＡＣＭ组及ＬＤＬ－ＡＣＭ复合物组荷腹水型肝癌Ｈ２２小鼠的平均生存时间分别为２４．６±７．５０ｄ，２３．４±７．６７ｄ和１７．１±３．４４ｄ。ＡＣＭ组和ＬＤＬ－ＡＣＭ复合物组荷瘤小鼠存活期均明显长于对照组（Ｐ＜０．０５，Ｐ＜０．０１），ＬＤＬ－ＡＣＭ复合物组效果好于ＡＣＭ组（Ｐ＜０．０５）。
A mouse subcutaneous solid tumor and ascitic hepatoma H22 model was established. The anti-tumor effect of LDL-ACM complex and aclarubicin (ACM) in tumor-bearing mice was observed. The results showed that: (1) In the control group, the solid tumor weight of H22 was 1.74±0.60 g, that of ACM was 1.30±0.57 g, and that of LDL-ACM complex was 0.86±0.44 g. There was a significant difference between the two groups (P<0.05), and there was no significant difference between the two groups (P>0.05). (2) The control group, ACM group and LDL-ACM complex group were ascites type liver cancer in H22 mice. The average survival time was 24.6±7.50d, 23.4±7.67d and 17.1±3.44d, respectively. The survival time of tumor-bearing mice in the ACM group and the LDL-ACM complex group was significantly longer than that in the control group (P<0.05, P<0.01), and the effect of the LDL-ACM complex group was better than that of the ACM group (P<0. 05).